Results in The Journal of American Dental Association showed the non-opioid combination provided superior pain relief during ...

Tonix Pharmaceuticals (NASDAQ: TNXP) has appointed Gary Ainsworth as Vice President, market Access, as the company prepares for the potential FDA approval of TNX-102 SL, a non-opioid analgesic for ...

Medically reviewed by Lindsay Cook, PharmD Vicodin (hydrocodone-acetaminophen) and Percocet (oxycodone-acetaminophen) are ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Inservice education prepared pharmacists for discussions with physicians about opioid analgesics. Phase 3 centered on an automatic interchange from meperidine to an equianalgesic dose of morphine ...

In this study, pharmacogenomics and therapeutic drug monitoring were used to evaluate the clinical effectiveness of genotyping chronic pain patients on analgesic therapy. It was hypothesized that ...

LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in ...

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid ...

A combination of acetaminophen (Tylenol) and ibuprofen (Advil, Motrin) controls pain after wisdom tooth removal better than ...

Approximately $50.0 million of net revenue from sales of LUMRYZ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients ...